Mixed Hyperlipidemia
3
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Chong Kun Dang PharmaceuticalKorea - Seodaemun
1 program1
Atorvastatin 20mgPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chong Kun Dang PharmaceuticalAtorvastatin 20mg
MSDMK-0524A
Clinical Trials (2)
Total enrollment: 2,816 patients across 2 trials
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin
Start: Dec 2013Est. completion: Aug 2016476 patients
Phase 3Unknown
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Start: Jan 2006Est. completion: Aug 20102,340 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.